BACKGROUND. Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer. We conducted a randomized clinical trial to test this hypothesis and the clinical implications. METHODS. Patients with small-cell lung cancer were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of recombinant methionyl G-CSF to study the incidence of infection as manifested by fever with neutropenia (absolute neutrophil count, less than 1.0 x 10(9) per liter, with a temperature greater than or equal to 38.2 degrees C) resulting from up to six cycles of chemotherapy with cyclophosphamide, doxorubicin, and etoposide. The patients were randomly assigned to receive either placebo or G-CSF, with treatment beginning on day 4 and continuing through day 17 of a 21-day cycle. RESULTS. The safety of the study treatment could be evaluated in 207 of the 211 patients assigned to either drug, and its efficacy in 199. At least one episode of fever with neutropenia occurred in 77 percent of the placebo group, as compared with 40 percent of the G-CSF group (P less than 0.001). Over all cycles of chemotherapy, the median duration of grade IV neutropenia (absolute neutrophil count, less than 0.5 x 10(9) per liter) was six days with placebo as compared with one day with G-CSF. During cycles of blinded treatment, the number of days of treatment with intravenous antibiotics, the number of days of hospitalization, and the incidence of confirmed infections were reduced by approximately 50 percent when G-CSF was given, as compared with placebo. Mild-to-moderate medullary bone pain occurred in 20 percent of the patients receiving G-CSF. CONCLUSIONS. The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections; in the incidence, duration, and severity of grade IV neutropenia; and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.
Source Information
Duke University Medical Center, Durham, N.C. 27710.
This article has been cited by other articles:
Tuffaha, H. W, Treish, I. M, Zaru, L.
(2008). The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. J Oncol Pharm Pract
14: 131-138
[Abstract]
Ip, E. J., Lee-Ma, A., Troxell, L. S., Chan, J.
(2008). Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Am J Health Syst Pharm
65: 1552-1555
[Abstract][Full Text]
Sasaki, K., Kuroda, R., Ishida, K., Kubo, S., Matsumoto, T., Mifune, Y., Kinoshita, K., Tei, K., Akisue, T., Tabata, Y., Kurosaka, M.
(2008). Enhancement of Tendon-Bone Osteointegration of Anterior Cruciate Ligament Graft Using Granulocyte Colony-Stimulating Factor. Am J Sports Med
36: 1519-1527
[Abstract][Full Text]
Barbour, S. Y.
(2008). Caring for the treatment-experienced breast cancer patient: The pharmacist's role. Am J Health Syst Pharm
65: S16-S22
[Abstract][Full Text]
Ziepert, M., Schmits, R., Trumper, L., Pfreundschuh, M., Loeffler, M., On behalf of the German High-Grade Non-Hodgkin's L,
(2008). Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol
19: 752-762
[Abstract][Full Text]
Timmer-Bonte, J. N.H., Adang, E. M.M., Termeer, E., Severens, J. L., Tjan-Heijnen, V. C.G.
(2008). Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy. JCO
26: 290-296
[Abstract][Full Text]
Sung, L., Nathan, P. C., Alibhai, S. M.H., Tomlinson, G. A., Beyene, J.
(2007). Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection. ANN INTERN MED
147: 400-411
[Abstract][Full Text]
Kuderer, N. M., Dale, D. C., Crawford, J., Lyman, G. H.
(2007). Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. JCO
25: 3158-3167
[Abstract][Full Text]
Ozer, H., Mirtsching, B., Rader, M., Luedke, S., Noga, S. J., Ding, B., Dreiling, L.
(2007). Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use. The Oncologist
12: 484-494
[Abstract][Full Text]
Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., Grann, V. R.
(2007). Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. JNCI J Natl Cancer Inst
99: 196-205
[Abstract][Full Text]
Dekker, A., Bulley, S., Beyene, J., Dupuis, L. L., Doyle, J. J., Sung, L.
(2006). Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation. JCO
24: 5207-5215
[Abstract][Full Text]
Hupperets, P. S., Tjan-Heijnen, V. C.
(2006). Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?. Ann Oncol
17: 1181-1183
[Full Text]
Timmer-Bonte, J. N.H., Adang, E. M.M., Smit, H. J.M., Biesma, B., Wilschut, F. A., Bootsma, G. P., de Boo, T. M., Tjan-Heijnen, V. C.G.
(2006). Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer. JCO
24: 2991-2997
[Abstract][Full Text]
Jacene, H. A., Ishimori, T., Engles, J. M., Leboulleux, S., Stearns, V., Wahl, R. L.
(2006). Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies. JNM
47: 950-956
[Abstract][Full Text]
Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., Georgala, A., Klastersky, J.
(2006). Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol
17: 507-514
[Abstract][Full Text]
Weycker, D., Hackett, J., Edelsberg, J. S, Oster, G., Glass, A. G
(2006). Are Shorter Courses of Filgrastim Prophylaxis Associated with Increased Risk of Hospitalization?. The Annals of Pharmacotherapy
40: 402-407
[Abstract][Full Text]
Du, X. L., Lairson, D. R., Begley, C. E., Fang, S.
(2005). Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort. JCO
23: 8620-8628
[Abstract][Full Text]
Timmer-Bonte, J. N., de Boo, T. M., Smit, H. J., Biesma, B., Wilschut, F. A., Cheragwandi, S. A., Termeer, A., Hensing, C. A., Akkermans, J., Adang, E. M., Bootsma, G. P., Tjan-Heijnen, V. C.
(2005). Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study. JCO
23: 7974-7984
[Abstract][Full Text]
Papaldo, P., Lopez, M., Marolla, P., Cortesi, E., Antimi, M., Terzoli, E., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Carlini, P., Nistico, C., Conti, F., Di Lauro, L., Botti, C., Di Filippo, F., Fabi, A., Giannarelli, D., Calabresi, F.
(2005). Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. JCO
23: 6908-6918
[Abstract][Full Text]
Djulbegovic, B., Frohlich, A., Bennett, C. L.
(2005). Acting on Imperfect Evidence: How Much Regret Are We Ready to Accept?. JCO
23: 6822-6825
[Full Text]
Ioannidis, J. P. A.
(2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA
294: 218-228
[Abstract][Full Text]
Lyman, G. H., Lyman, C. H., Agboola, O., for the Anc Study Group,
(2005). Risk Models for Predicting Chemotherapy-Induced Neutropenia. The Oncologist
10: 427-437
[Abstract][Full Text]
Lorigan, P., Woll, P. J., O'Brien, M. E. R., Ashcroft, L. F., Sampson, M. R., Thatcher, N.
(2005). Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer. JNCI J Natl Cancer Inst
97: 666-674
[Abstract][Full Text]
Tannock, I.
(2005). Features of a High Quality Phase 3 Trial. aacredbook
2005: 207-210
[Full Text]
Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., Neumann, T. A., Schwartzberg, L. S.
(2005). First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. JCO
23: 1178-1184
[Abstract][Full Text]
Blayney, D. W., McGuire, B. W., Cruickshank, S. E., Johnson, D. H.
(2005). Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non-Small Cell Lung Cancer and Non-Hodgkin's Lymphoma. The Oncologist
10: 138-149
[Abstract][Full Text]
Ardizzoni, A., Favaretto, A., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., Pari, F., Tibaldi, C., Altieri, A. M., Barbera, S., Cacciani, G., Raimondi, M., Tixi, L., Stefani, M., Monfardini, S., Antilli, A., Rosso, R., Paccagnella, A.
(2005). Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis--A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study. JCO
23: 569-575
[Abstract][Full Text]
Kazama, T., Faria, S. C., Varavithya, V., Phongkitkarun, S., Ito, H., Macapinlac, H. A.
(2005). FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls. RadioGraphics
25: 191-207
[Abstract][Full Text]
Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., Fisher, R. I.
(2004). Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. JCO
22: 4302-4311
[Abstract][Full Text]
Engel, C., Scholz, M., Loeffler, M.
(2004). A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood
104: 2323-2331
[Abstract][Full Text]
Sung, L., Nathan, P. C., Lange, B., Beyene, J., Buchanan, G. R.
(2004). Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials. JCO
22: 3350-3356
[Abstract][Full Text]
Kuramoto, K., Follmann, D. A., Hematti, P., Sellers, S., Agricola, B. A., Metzger, M. E., Donahue, R. E., von Kalle, C., Dunbar, C. E.
(2004). Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood
103: 4070-4077
[Abstract][Full Text]
Bhatt, V., Saleem, A.
(2004). Drug-Induced Neutropenia - Pathophysiology, Clinical Features, and Management. Annals of Clinical & Laboratory Science
34: 131-137
[Abstract][Full Text]
Lyman, G. H., Dale, D. C., Crawford, J.
(2003). Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. JCO
21: 4524-4531
[Abstract][Full Text]
Doorduijn, J.K., van der Holt, B., van Imhoff, G.W., van der Hem, K.G., Kramer, M.H.H., van Oers, M.H.J., Ossenkoppele, G.J., Schaafsma, M.R., Verdonck, L.F., Verhoef, G.E.G., Steijaert, M.M.C., Buijt, I., Uyl-de Groot, C.A., van Agthoven, M., Mulder, A.H., Sonneveld, P.
(2003). CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma. JCO
21: 3041-3050
[Abstract][Full Text]
Vadhan-Raj, S., Patel, S., Bueso-Ramos, C., Folloder, J., Papadopolous, N., Burgess, A., Broemeling, L. D., Broxmeyer, H. E., Benjamin, R. S.
(2003). Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia. JCO
21: 3158-3167
[Abstract][Full Text]
Omura, G. A., Brady, M. F., Look, K. Y., Averette, H. E., Delmore, J. E., Long, H. J., Wadler, S., Spiegel, G., Arbuck, S. G.
(2003). Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study. JCO
21: 2843-2848
[Abstract][Full Text]
Wunderlich, A., Kloess, M., Reiser, M., Rudolph, C., Truemper, L., Bittner, S., Schmalenberg, H., Schmits, R., Pfreundschuh, M., Loeffler, M.
(2003). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol
14: 881-893
[Abstract][Full Text]
Stanford, B. L, Zondor, S. D, Cobos, E.
(2003). Is pegfilgrastim appropriate for the treatment of established febrile neutropenia?. J Oncol Pharm Pract
9: 113-119
[Abstract]
Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., Holte, H., Myhre, J., Pertovaara, H., Bjorkholm, M.
(2003). CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood
101: 3840-3848
[Abstract][Full Text]
Mitchell, P. L. R., Basser, R., Chipman, M., Grigg, A., Cebon, J., Davis, I. D., Zalcberg, J., Ng, S., Appia, F., Green, M.
(2003). A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours. Ann Oncol
14: 788-794
[Abstract][Full Text]
Tjan-Heijnen, V. C. G., Caleo, S., Postmus, P. E., Ardizzoni, A., Burghouts, J. T. M., Buccholz, E., Biesma, B., Gorlia, T., Crott, R., Giaccone, G., Debruyne, C., Manegold, C.
(2003). Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol
14: 248-257
[Abstract][Full Text]
Vose, J.M., Crump, M., Lazarus, H., Emmanouilides, C., Schenkein, D., Moore, J., Frankel, S., Flinn, I., Lovelace, W., Hackett, J., Liang, B.C.
(2003). Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. JCO
21: 514-519
[Abstract][Full Text]
Crawford, J.
(2003). Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol
14: 6-7
[Full Text]
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., Zani, V., Liang, B. C., Renwick, J., Piccart, M. J.
(2003). A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol
14: 29-35
[Abstract][Full Text]
BitMansour, A., Burns, S. M., Traver, D., Akashi, K., Contag, C. H., Weissman, I. L., Brown, J. M. Y.
(2002). Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood
100: 4660-4667
[Abstract][Full Text]
Tjan-Heijnen, V. C. G., Wagener, D. J. T., Postmus, P. E.
(2002). An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol
13: 1519-1530
[Abstract][Full Text]
Ardizzoni, A., Tjan-Heijnen, V. C.G., Postmus, P. E., Buchholz, E., Biesma, B., Karnicka-Mlodkowska, H., Dziadziuszko, R., Burghouts, J., van Meerbeeck, J. P., Gans, S., Legrand, C., Debruyne, C., Giaccone, G., Manegold, C.
(2002). Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial--08923. JCO
20: 3947-3955
[Abstract][Full Text]
Holmes, F. A., Jones, S. E., O'Shaughnessy, J., Vukelja, S., George, T., Savin, M., Richards, D., Glaspy, J., Meza, L., Cohen, G., Dhami, M., Budman, D. R., Hackett, J., Brassard, M., Yang, B. B., Liang, B. C.
(2002). Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol
13: 903-909
[Abstract][Full Text]
Takatsuka, H., Takemoto, Y., Mori, A., Okamoto, T., Kanamaru, A., Kakishita, E.
(2002). Common Features in the Onset of ARDS After Administration of Granulocyte Colony-Stimulating Factor*. Chest
121: 1716-1720
[Abstract][Full Text]
Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S., Jones, S.E., Shogan, J., Savin, M., Glaspy, J., Moore, M., Meza, L., Wiznitzer, I., Neumann, T.A., Hill, L.R., Liang, B.C.
(2002). Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer. JCO
20: 727-731
[Abstract][Full Text]
Kerbel, R. S., Klement, G., Pritchard, K. I., Kamen, B.
(2002). Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol
13: 12-15
[Full Text]
Patte, C., Laplanche, A., Bertozzi, A. I., Baruchel, A., Frappaz, D., Schmitt, C., Mechinaud, F., Nelken, B., Boutard, P., Michon, J.
(2002). Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin's Lymphoma: A Randomized Study of the French Society of Pediatric Oncology. JCO
20: 441-448
[Abstract][Full Text]
Osterlind, K.
(2001). Chemotherapy in small cell lung cancer. Eur Respir J
18: 1026-1043
[Abstract][Full Text]
Wilson-Royalty, M., Lawless, G., Palmer, C., Brown, R.
(2001). Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract
7: 141-147
[Abstract]
Farese, A. M., Casey, D. B., Smith, W. G., Vigneulle, R. M., McKearn, J. P., MacVittie, T. J.
(2001). Leridistim, a Chimeric Dual G-CSF and IL-3 Receptor Agonist, Enhances Multilineage Hematopoietic Recovery in a Nonhuman Primate Model of Radiation-Induced Myelosuppression: Effect of Schedule, Dose, and Route of Administration. Stem Cells
19: 522-533
[Abstract][Full Text]
Zamboni, W. C., D'Argenio, D. Z., Stewart, C. F., MacVittie, T., Delauter, B. J., Farese, A. M., Potter, D. M., Kubat, N. M., Tubergen, D., Egorin, M. J.
(2001). Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia. Clin. Cancer Res.
7: 2301-2308
[Abstract][Full Text]
Farese, A. M., Smith, W. G., Giri, J. G., Siegel, N., McKearn, J. P., MacVittie, T. J.
(2001). Promegapoietin-1a, an Engineered Chimeric IL-3 and Mpl-L Receptor Agonist, Stimulates Hematopoietic Recovery in Conventional and Abbreviated Schedules Following Radiation-Induced Myelosuppression in Nonhuman Primates. Stem Cells
19: 329-338
[Abstract][Full Text]
Woll, P. J., Thatcher, N., Lomax, L., Hodgetts, J., Lee, S. M., Burt, P. A., Stout, R., Simms, T., Davies, R., Pettengell, R.
(2001). Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients. JCO
19: 712-719
[Abstract][Full Text]
Garcia-Carbonero, R., Mayordomo, J. I., Tornamira, M. V., Lopez-Brea, M., Rueda, A., Guillem, V., Arcediano, A., Yubero, A., Ribera, F., Gomez, C., Tres, A., Perez-Gracia, J. L., Lumbreras, C., Hornedo, J., Cortes-Funes, H., Paz-Ares, L.
(2001). Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial. JNCI J Natl Cancer Inst
93: 31-38
[Abstract][Full Text]
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro,
(2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO
18: 3558-3585
[Full Text]
Johnston, E., Crawford, J., Blackwell, S., Bjurstrom, T., Lockbaum, P., Roskos, L., Yang, B.-B., Gardner, S., Miller-Messana, M. A., Shoemaker, D., Garst, J., Schwab, G.
(2000). Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy. JCO
18: 2522-2528
[Abstract][Full Text]
Vadhan-Raj, S., Verschraegen, C. F., Bueso-Ramos, C., Broxmeyer, H. E., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Gershenson, D., Jones, D., Ashby, M., Kavanagh, J. J.
(2000). Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer. ANN INTERN MED
132: 364-368
[Abstract][Full Text]
van Os, R., Robinson, S., Sheridan, T., Mauch, P. M.
(2000). Granulocyte-Colony Stimulating Factor Impedes Recovery from Damage Caused by Cytotoxic Agents through Increased Differentiation at the Expense of Self-Renewal. Stem Cells
18: 120-127
[Abstract][Full Text]
MacVittie, T. J., Farese, A. M., Smith, W. G., Baum, C. M., Burton, E., McKearn, J. P.
(2000). Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood
95: 837-845
[Abstract][Full Text]
Blot, E., Heron, F., Lishner, M., Rubenstein, E. B., Rolston, K. V.I., Kim, Y. J., Sezer, O., Freifeld, A. G., Steinberg, S. M., Pizzo, P. A., Kern, W. V., Cometta, A., Finberg, R. W., Talcott, J. A.
(2000). Oral Antibiotics for Febrile Patients with Neutropenia Due to Cancer Chemotherapy. NEJM
342: 55-58
[Full Text]
Elias, A.
(1999). Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer*. Chest
116: 531S-538S
[Abstract][Full Text]
Miller, L. L., Korn, E. L., Stevens, D. S., Janik, J. E., Gause, B. L., Kopp, W. C., Holmlund, J. T., Curti, B. D., Sznol, M., Smith, J. W. II, Urba, W. J., Donegan, S. E., Watson, T. M., Longo, D. L.
(1999). Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin. Blood
93: 3250-3258
[Abstract][Full Text]
Opal, S. M., Jhung, J. W., Keith, J. C. Jr, Goldman, S. J., Palardy, J. E., Parejo, N. A.
(1999). Additive Effects of Human Recombinant Interleukin-11 and Granulocyte Colony-Stimulating Factor in Experimental Gram-Negative Sepsis. Blood
93: 3467-3472
[Abstract][Full Text]
Shpall, E. J., Wheeler, C. A., Turner, S. A., Yanovich, S., Brown, R. A., Pecora, A. L., Shea, T. C., Mangan, K. F., Williams, S. F., LeMaistre, C. F., Long, G. D., Jones, R., Davis, M. W., Murphy-Filkins, R., Parker, W. R.L., Glaspy, J. A.
(1999). A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients. Blood
93: 2491-2501
[Abstract][Full Text]
Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U., Loeffler, M.
(1998). Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group. Blood
92: 4560-4567
[Abstract][Full Text]
van Os, R., Robinson, S., Sheridan, T., Mislow, J. M.K., Dawes, D., Mauch, P. M.
(1998). Granulocyte Colony-Stimulating Factor Enhances Bone Marrow Stem Cell Damage Caused by Repeated Administration of Cytotoxic Agents. Blood
92: 1950-1956
[Abstract][Full Text]
Carpenter, C. E., Johnson, N. E., Rosenfeld, J. F.
(1998). The Impact of Climcal Guidelines On Practice Patterns: Doing More versus Doing Less. American Journal of Medical Quality
13: 98-103
[Abstract]
Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J., Barge, A.
(1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood
90: 4710-4718
[Abstract][Full Text]
Talcott, J. A.
(1997). Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?. The Oncologist
2: 365-373
[Abstract][Full Text]
Abraham, R., Basser, R. L.
(1997). Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies. The Oncologist
2: 311-318
[Abstract][Full Text]
Pajkrt, D., Manten, A., van der Poll, T., Tiel-van Buul, M. M.C., Jansen, J., Wouter ten Cate, J., J.H. van Deventer, S.
(1997). Modulation of Cytokine Release and Neutrophil Function by Granulocyte Colony-Stimulating Factor During Endotoxemia in Humans. Blood
90: 1415-1424
[Abstract][Full Text]
Geissler, K., Koller, E., Hubmann, E., Niederwieser, D., Hinterberger, W., Geissler, D., Kyrle, P., Knobl, P., Pabinger, I., Thalhammer, R., Schwarzinger, I., Mannhalter, C., Jaeger, U., Heinz, R., Linkesch, W., Lechner, K.
(1997). Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia --- A Randomized Phase-III Study. Blood
90: 590-596
[Abstract][Full Text]
Hartmann, L. C., Tschetter, L. K., Habermann, T. M., Ebbert, L. P., Johnson, P. S., Mailliard, J. A., Levitt, R., Suman, V. J., Witzig, T. E., Wieand, H.S., Miller, L. L., Moertel, C. G., Grendahl, D. C., Herrera, D. M.
(1997). Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia. NEJM
336: 1776-1780
[Abstract][Full Text]
Pui, C.-H., Boyett, J. M., Hughes, W. T., Rivera, G. K., Hancock, M. L., Sandlund, J. T., Synold, T., Relling, M. V., Ribeiro, R. C., Crist, W. M., Evans, W. E.
(1997). Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. NEJM
336: 1781-1787
[Abstract][Full Text]
Howitt, K. M, Matthews, J. P
(1997). A clinical and economic drug usage evaluation of prophylactic G-CSF in non-Hodgkin's lymphoma. J Oncol Pharm Pract
3: 68-75
[Abstract]
Basser, R. L., Rasko, J. E.J., Clarke, K., Cebon, J., Green, M. D., Grigg, A. P., Zalcberg, J., Cohen, B., O'Byrne, J., Menchaca, D. M., Fox, R. M., Begley, C. G.
(1997). Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer. Blood
89: 3118-3128
[Abstract][Full Text]
van Os, R., Dawes, D., Mislow, J. M.K., Witsell, A., Mauch, P. M.
(1997). Host Conditioning With 5-Fluorouracil and kit-Ligand to Provide for Long-Term Bone Marrow Engraftment. Blood
89: 2376-2383
[Abstract][Full Text]
Moore, J. O., Dodge, R. K., Amrein, P. C., Kolitz, J., Lee, E. J., Powell, B., Godfrey, S., Robert, F., Schiffer, C. A.
(1997). Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022 . Blood
89: 780-788
[Abstract][Full Text]
Veltri, S., Smith, J. W. II
(1996). Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects. The Oncologist
1: 190-200
[Abstract][Full Text]
Veltri, S, Smith, J. 2nd
(1996). Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells
14: 164-176
[Abstract]
Tivnann, H. A., Gaines-Gas, R., Thorpe, R., Mire-Sluis, A. R.
(1996). An evaluation of the stability of granulocyte colony stimulating factor on short-term storage and delivery from an elastomeric infusion system. J Oncol Pharm Pract
2: 107-112
[Abstract]
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., Schiffer, C. A., The Cancer and Leukemia Group B,
(1995). Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia. NEJM
332: 1671-1677
[Abstract][Full Text]
Smith, J. W., Longo, D. L., Alvord, W. G., Janik, J. E., Sharfman, W. H., Gause, B. L., Curti, B. D., Creekmore, S. P., Holmlund, J. T., Fenton, R. G., Sznol, M., Miller, L. L., Shimizu, M., Oppenheim, J. J., Fiem, S. J., Hursey, J. C., Powers, G. C., Urba, W. J.
(1993). The Effects of Treatment with Interleukin-1{alpha} on Platelet Recovery after High-Dose Carboplatin. NEJM
328: 756-761
[Abstract][Full Text]
Aaronson, S.
(1991). Growth factors and cancer. Science
254: 1146-1153
[Abstract]
Previous
